ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
前收盤價
US$7.36
−US$0.34 · -4.42%
盤中時間採用ET。市場資料可能有所延遲。
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
日內區間
目前US$7.36
52週區間
目前US$7.36
盤中時間採用ET。市場資料可能有所延遲。
ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.
日內區間
目前US$7.36
52週區間
目前US$7.36
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 122萬 USD | 110.7萬 USD | 103.2萬 USD | — | — |
| 毛利 | −122萬 USD | −110.7萬 USD | −103.2萬 USD | — | — |
| 研究與開發 | 1.1億 USD | 1.14億 USD | 8517.2萬 USD | 6168萬 USD | 5685.8萬 USD |
| 銷售、一般及管理費用 | 3318.6萬 USD | 2882.3萬 USD | 2560.8萬 USD | 2508.7萬 USD | 2201.3萬 USD |
| 營業費用 | 1.42億 USD | 1.42億 USD | 1.1億 USD | 9176.7萬 USD | 7887.1萬 USD |
| 利息收入 | — | — | 1008.3萬 USD | 264.5萬 USD | 14.1萬 USD |
| 利息支出 | — | — | — | 264.5萬 USD | — |
| 折舊和攤銷 | 122萬 USD | 110.7萬 USD | 103.2萬 USD | 96.6萬 USD | 89.7萬 USD |
| 營業利益 | −1.43億 USD | −1.43億 USD | −1.11億 USD | −9176.7萬 USD | −7887.1萬 USD |
| 淨利 | −1.29億 USD | −1.28億 USD | −1.01億 USD | −8912.2萬 USD | −7871.5萬 USD |
公司資料更新於 2026年11月22日。
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$22.20
上漲空間 201.63%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2157.22萬0.00%6893億 USD0.03%US$340.02-3.52%
State Street SPDR S&P Biotech ETFXBI1908.11萬0.20%96.36億 USD0.35%US$140.18-2.73%
iShares Russell 2000 ETFIWM1483.6萬0.02%715.37億 USD0.19%US$256.61-2.88%
Vanguard Extended Market ETFVXF951.33萬0.01%302億 USD0.05%US$211.44-3.21%
Dimensional - US Small Cap ETFDFAS551.71萬0.02%312.35億 USD0.30%US$74.24-2.48%
Vanguard Russell 2000 ETFVTWO406.3萬0.02%168億 USD0.06%US$103.76-2.76%
iShares Biotechnology ETFIBB388.98萬0.04%105.27億 USD0.44%US$199.54-2.05%
Schwab U.S. Small-Cap ETFSCHA361.38萬0.02%204.47億 USD0.03%US$30.51-2.83%
Vanguard Morningstar Total Stock Market ETFVTI
State Street SPDR S&P Biotech ETFXBI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
Dimensional - US Small Cap ETFDFAS
Vanguard Russell 2000 ETFVTWO
iShares Biotechnology ETFIBB
Schwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。